Reports Q1 revenue $27.178M, consensus $25.9M. “We are pleased to report another strong quarter of launch performance from LUMRYZ as we continue to serve the narcolepsy patient community. The continued positive feedback we hear daily from patients, prescribers and caregivers builds on the strong commercial foundation we established early into the launch,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. “Over the course of 2024, we will be laser focused on the continued market growth of LUMRYZ for the treatment of narcolepsy as well as potentially expanding to the pediatric population and initiating our Phase 3 pivotal trial in idiopathic hypersomnia in the second half of the year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Is AVDL a Buy, Before Earnings?
- Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
- Avadel Pharmaceuticals call buyer realizes 17% same-day gains
- Avadel Pharmaceuticals Shifts to Nasdaq, Ends ADR Program
- Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference